Morepen Laboratories Limited Press Release Sep 28 2026
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Morepen Laboratories Limited has submitted its first Abbreviated New Drug Application to the U.S. FDA for Sitagliptin Tablets, marking a significant milestone in its integrated CDMO capabilities. This submission enhances Morepen's expertise in API and finished dosage development, supporting specialized CDMO opportunities across regulated markets. The company aims to build on this foundation through customer development programs and technology transfer, expanding its capabilities in global pharmaceutical partnerships.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Morepen Laboratories Limited on 6ix
Earlier from Morepen Laboratories
- Q1'FY27 Investor Presentations
- Morepen Laboratories Limited Press Release Jul 01 2026
- Press Release May 27 2026
- Press Release Apr 17 2026
- Press Release Feb 23 2026
Later from Morepen Laboratories
- Morepen Laboratories Limited has informed the Exchange regarding a press release dated October 27, 2026, titled "Morepen hits record Q2 revenue of Rs. 755 Cr; EBITDA surges 273% to Rs. 132 Cr; CDMO momentum drives Morepen into a new earnings scale; H1 EBITDA reaches Rs. 220 Cr".
- Morepen Laboratories Limited has informed the Exchange regarding a press release dated November 09, 2026, titled "Morepen enters U.S. prescription generics market, building on its established API strengths".
Follow Morepen Laboratories into a list and get an email when it puts out news.
Follow Morepen Laboratories